A detailed history of Rafferty Asset Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 140,835 shares of NBIX stock, worth $19.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
140,835
Previous 122,998 14.5%
Holding current value
$19.1 Million
Previous $16.9 Million 4.25%
% of portfolio
0.06%
Previous 0.06%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $2.04 Million - $2.73 Million
17,837 Added 14.5%
140,835 $16.2 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $7.48 Million - $8.18 Million
57,128 Added 86.73%
122,998 $16.9 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $1.39 Million - $1.53 Million
-10,679 Reduced 13.95%
65,870 $9.08 Million
Q4 2023

Feb 13, 2024

SELL
$106.07 - $132.76 $524,091 - $655,967
-4,941 Reduced 6.06%
76,549 $10.1 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $709,004 - $883,051
-7,541 Reduced 8.47%
81,490 $9.17 Million
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $1.62 Million - $1.89 Million
18,043 Added 25.42%
89,031 $8.4 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $219,652 - $287,128
2,334 Added 3.4%
70,988 $7.19 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $376,188 - $447,886
3,525 Added 5.41%
68,654 $8.2 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $2.28 Million - $2.67 Million
24,727 Added 61.2%
65,129 $6.92 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.48 Million - $1.95 Million
-19,494 Reduced 32.55%
40,402 $3.94 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $456,724 - $597,682
-6,304 Reduced 9.52%
59,896 $5.62 Million
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $2.71 Million - $3.61 Million
33,986 Added 105.5%
66,200 $5.64 Million
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $496,741 - $570,808
5,764 Added 21.79%
32,214 $3.09 Million
Q2 2021

Aug 10, 2021

SELL
$89.43 - $102.27 $705,244 - $806,501
-7,886 Reduced 22.97%
26,450 $2.57 Million
Q1 2021

May 10, 2021

BUY
$87.57 - $119.4 $2.1 Million - $2.87 Million
24,002 Added 232.26%
34,336 $3.34 Million
Q4 2020

Feb 10, 2021

SELL
$86.91 - $108.33 $819,735 - $1.02 Million
-9,432 Reduced 47.72%
10,334 $991,000
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $828,995 - $1.17 Million
8,621 Added 77.35%
19,766 $1.9 Million
Q2 2020

Aug 07, 2020

BUY
$85.09 - $130.36 $584,057 - $894,791
6,864 Added 160.34%
11,145 $1.36 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $2.35 Million - $3.56 Million
-31,334 Reduced 87.98%
4,281 $371,000
Q4 2019

Feb 10, 2020

SELL
$86.8 - $118.57 $2.75 Million - $3.75 Million
-31,629 Reduced 47.04%
35,615 $3.83 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $697,801 - $844,987
8,325 Added 14.13%
67,244 $6.06 Million
Q2 2019

Aug 09, 2019

SELL
$72.24 - $91.27 $405,338 - $512,115
-5,611 Reduced 8.7%
58,919 $4.98 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $4.47 Million - $5.91 Million
64,530 New
64,530 $5.69 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.